StemoniX’s microBrain® and microHeart® Platforms to be Featured in Podium Presentation at the PREDiCT: 4th Annual 3D Tissue Models Summit StemoniX's Research and Development Director, Fabian Zanella, Ph.D., to present during the session "Physiologically-relevant 3D hiPSC-based platforms empowering drug discovery"

StemoniX microBrain® and microHeart® Platforms to be Featured in Podium Presentation at the PREDiCT: 4th Annual 3D Tissue Models Summit

StemoniX’s Research and Development Director, Fabian Zanella, Ph.D., to present during the session “Physiologically-relevant 3D hiPSC-based platforms empowering drug discovery”

 

MAPLE GROVE, Minn.Sept. 3, 2019 – StemoniX® a biotech company revolutionizing how new medicines are discovered, announced today the opening of its new, state-of-the-art research & development (R&D) facility in La Jolla, CA. The facility will house StemoniX’s research team, who will concentrate on developing new preclinical applications, disease modeling techniques, and drug discovery opportunities involving the company’s high-throughput microOrgan technology platforms.

 

microOrgans are the world’s first ready-to-use assay plates containing living microtissues engineered from human induced pluripotent stem cells (hiPSC). Designed to enable high-throughput human drug screening without the need for drugs to enter a human body, microOrgans, including microBrain® and microHeart®, offer the potential to deliver significant cost and time savings to the pharmaceutical industry by enhancing the safety, consistency, and accuracy of human clinical trials that today rely on animal models and limited human testing as predictors of drug interactions across an entire patient population.

 

Ping Yeh, co-founder and CEO of StemoniX, said: “The PREDiCT: 4th Annual 3D Tissue Models Summit is an ideal event to showcase the potential of our technology to fundamentally alter and accelerate the development of therapeutics. As presented by Dr. Zanella, the StemoniX microBrain and microHeart platforms, engineered from human skin cells, enable high-throughput preclinical drug screening in a human system without the need for drugs to enter a human body. This capability, combined with StemoniX’s scalable, high-volume manufacturing processes, offers the potential to deliver significant time and cost savings to the pharmaceutical industry while, at the same time, enhancing the safety, consistency, and accuracy of human clinical trials, which today rely on animal models and small human samples as predictors of drug interactions across an entire patient population.”

 

Podium Presentation Details

Title:

Expertise Insight by StemoniX

Session:

Physiologically-relevant 3D hiPSC-based platforms empowering drug discovery

Event

PREDiCT: 4th Annual 3D Tissue Models Summit

Date:

Sept. 5, 2019

Time:

10 a.m. – 10:30 a.m., EDT

Location:

Boston, MA

 

About StemoniX

StemoniX is empowering the discovery of new medicines to treat challenging diseases via the world’s first ready-to-use assay plates containing living human microOrgans®, including electrophysiologically active neural (microBrain®) and cardiac (microHeart®) cells. Predictive, accurate, and consistent, StemoniX’s products enable pharmaceutical scientists to quickly and economically conduct high-throughput screening in a simplified workflow. Through their Discovery as a Service branch, the company also partners with organizations to screen compounds as well as create customized microOrgan models and assays tailored to individual discovery and toxicity needs. Visit www.stemonix.com to learn how StemoniX is helping global institutions humanize drug discovery and development to bring the most promising medicines to patients.

 

Investor Contact:
Tirth Patel
Tiberend Strategic Advisors, Inc.
+1.212.375.2694

tpatel@tiberend.com

 

Media Contact:
Ingrid Mezo
Tiberend Strategic Advisors, Inc.
+1.646.604.5150

imezo@tiberend.com

 

Interested in getting in touch? Send us an email info@stemonix.com and we will be happy to get back to you.